Carbon monoxide-releasing molecule attenuates allograft airway rejection

Takashi Ohtsuka, Kaoru Kaseda, Takao Shigenobu, Tai Hato, Ikuo Kamiyama, Taichiro Goto, Mitsutomo Kohno, Masayuki Shimoda

研究成果: Article査読

8 被引用数 (Scopus)


Acute rejection after lung transplantation is the main risk factor for the development of bronchiolitis obliterans (BO). Carbon monoxide (CO) can provide anti-inflammatory effects and may serve to limit tissue injury in airway transplant. Here, we tested the ability of carbon monoxide releasing molecule-2 (CORM-2) to prevent airway rejection. Tracheal grafts from BALB/c or C57BL/6 were transplanted to C57BL/6 recipients. Experimental groups were treated with multiple doses of CORM-2. Histopathological evaluation of luminal obliteration was blindly reviewed. Immunohistochemistry and real-time RT-PCR analyses were performed. Allografts treated with CORM-2 revealed a striking reduction of thickening in epithelial and subepithelial airway layers (P < 0.01) at day 7 in orthotopic trachea transplantation model compared with allografts treated with vehicle. In heterotopic trachea transplantation model, CORM-2 treated allografts showed a reduction of luminal obliteration (P < 0.01) at days 14 and 21. There was also a concordant decrease in CD3+ lymphocytes and macrophages in CORM-2 treated allografts. IFN-γ, IL-2 and IL17A mRNA expressions were reduced dramatically by systemic administration of CORM-2. These data implicate CORM-2-derived CO has an important protective function in experimental BO, and may represent a target for the therapeutic intervention of chronic lung allograft rejection.

ジャーナルTransplant International
出版ステータスPublished - 2014 7月

ASJC Scopus subject areas

  • 移植


「Carbon monoxide-releasing molecule attenuates allograft airway rejection」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。